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a b s t r a c t
Aim of the study: We present the preliminary results of the study focused on the impact of
subthalamic deep brain stimulation (DBS-STN) on sleep and other non-motor symptoms
(NMS).
Materials and methods: Ten patients with advanced PD, underwent two-night polysomno-
graphy (PSG) mean 1.1 week before surgery and 6.2 months post DBS programming. NMS
were assessedwith a set of scales before surgery and 6months and 12months following DBS
programming.
Results: Contrary to previous studies, we noted deterioration of sleep pattern in the follow-
up PSG. We found a decrease in total sleep time, duration of the stage N2, with prolongation
of stage N1 and wakefulness after sleep onset. We did not detect any impact of DBS-STN on
subjective severity of restless legs syndrome. REM – sleep behavior disorder, however
reportedwas not observed in any patient during PSG evaluations.We also found statistically
signiﬁcant correlations between severity of sleep disturbances and quality of life, as well as,
between severity of motor symptoms and worse objective sleep quality.
Conclusions: We found that DBS-STN improved quality of life, subjective quality of sleep and
sleepiness, however, contrary to the previous studies the objective parameters of sleep
worsened after the surgery.
© 2018 Published by Elsevier Sp. z o.o. on behalf of Polish Neurological Society.* Corresponding author at: Neurology Department, St Adalbert Hospital Copernicus PL, Aleja Jana Pawła II 50, 80-462 Gdańsk, Poland.
E-mail address: jaroslawdulski@gmail.com (J. Dulski).
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disorder traditionally viewed as a primarily motor entity,
however, the spectrum of non-motor symptoms (NMS) is wide
and includes neuropsychiatric disturbances, cognitive deteri-
oration, sensory symptoms, autonomic dysfunction and sleep
and wakefulness disorders [ [6_TD$DIFF]1,2]. Many studies demonstrated
that NMS determine quality of life (QoL) and are more
debilitating than motor symptoms [[7_TD$DIFF]2,3]. Among NMS sleep
disturbances are one of the most important contributors to
poor quality of life of patients and their caregivers [[8_TD$DIFF]4,5].
Initial studies on the efﬁcacy of deep brain stimulation
(DBS) in PD focused almost solely on motor aspects and the
inﬂuence of STN (subthalamic nucleus) targeted DBS on NMS
and particularly sleep is thematter of only a few recent studies
including a small groups of patients.
Hence, we aim to explore effects of DBS-STN in PD patients,
with special emphasis on sleep.
2. Material and methodsTen advanced PD patients, 6 females and 4 males, with the
mean age of 59  8 years (range 45–68) and the mean disease
duration of 11  2 years, who fulﬁlled theDefer et al. [ [9_TD$DIFF]6] CAPSIT
– criteria to perform a routine DBS therapy (no preselection),
were included into the study. During preoperative evaluation
patients were hospitalized and underwent comprehensive
neuropsychological assessment (including Beck Depression
Inventory, BDI), brain magnetic resonance imaging and
levodopa challenge test. Non motor symptoms were assessed
with the use of Non-Motor Symptoms Scale (NMSS), Parkin-
son's Disease Sleep Scale (PDSS), Epworth Sleepiness Scale
(ESS), Single-Question Screen for RBD (RBD1Q), Parkinson's
Disease Quality of Life Questionnaire (PDQ-39). Patients who
fulﬁlled criteria of International RLS Study Group for the
diagnosis of RLS were additionally examined with Interna-
tional RLS Study Group Rating Scale (IRLS). Patients were
evaluated on two consecutive nights with PSG at a median of
1.1 week before surgery and again at a median of 6.2 months
post DBS programming. The ﬁrst nights were considered to be
adaptation nights and the obtained data were not analyzed,
except for 2 patients whose recordings from the second nights
were not valid due to the technical issues. All PSG studieswere
conducted in the sleep laboratory in the psychiatry clinic by a
PSG technician and scored by a physician certiﬁed in sleep
medicine (Polish Sleep Research Society Certiﬁcate). During
the PSG recordings we used 2 EOG channels, 6 EEG channels
(F3-A2, F4-A1, C3A2, C4-A1, O1-A2, O2-A), 3 EMG channels, 2
limb movement channels, 1 airﬂow channel, 1 ECG channel
and 1 oximetry channel. DBS programmingwas performed at a
median of 7 weeks post DBS implantation. The follow-up
outpatient evaluations were performed 6 months and 12
months following DBS programming. We used the Shapiro–
Wilk test to check whether the data followed normal
distribution, then parametric (t-test) and non-parametric
(Wilcoxon signed-rank and Mann–Whitney–Wilcoxon) tests
accordingly. We searched for correlations with the use ofKendall and Spearman's rank correlation coefﬁcient (Kendall's
tau coefﬁcient and Spearman's rho). The study was approved
by Independent Bioethics Commission for Research and we
obtained written informed consent from all patients.
3. ResultsDBS-STN in a statistically signiﬁcant manner ( p < 0.05)
reduced total sleep time and duration of the stage N2,
lengthened duration of the stage N1 and of the wake after
sleep onset (WASO).Moreover, an increase of the arousal index
(AI), improvement of the periodic limb movements index
(PLMI) and the apnea hypopnea index (AHI) were observed,
though these changes were not statistically signiﬁcant. No
ﬁndings typical of RBD were found on PSG evaluations and
REM atonia was preserved in all ten subjects.
The details of the subjects' characteristics compiled with
PSG data are presented in Table 1 and the complete results of
the preoperative and follow-up polysomnographic recordings
along with other non-motor and motor scales are displayed in
Table 2.
DBS-STN in a statistically relevant way alleviated non-
motor symptoms scores (NMSS) and improved quality of life
(PDQ39). DBS-STN improved subjective measures of sleep
quality (PDSS) and reduced sleepiness (ESS), however, these
differences were not statistically signiﬁcant. Four out of ten
patients fulﬁlled the criteria of International RLS Study Group
for the diagnosis of RLS throughout the study and their
symptoms remained relatively stable at follow up. At the
initial evaluation and 6 and 12months follow-ups, six, ﬁve and
eight patients, respectively, were suspected of RBD based on
interview and a positive answer to RBD1Q.
We found statistically signiﬁcant negative relationships
between severity of subjective sleep disturbances (PDSS),
NMSS scores and quality of life (PDQ39).We also demonstrated
signiﬁcant negative correlations between the severity ofmotor
symptoms (UPDRS part III) and objective sleep quality (as
assessed by sleep efﬁciency and WASO).
We did not detect any correlations between RLS (IRLS) and
sleep efﬁciency, sleep efﬁciency or RLS, age, disease duration
or dominant side and severity of non-motor symptoms.
4. DiscussionUntil now there have been only six studies published with the
polysomnography (PSG) evaluation in PD patients treatedwith
DBS-STN [ [9_TD$DIFF]6–[10_TD$DIFF] 1]. These studies were based on different designs
and most of them included small number of patients (from 5
up to 11) and only the recent one included 50 patients [ [11_TD$DIFF] 0],
therefore making it difﬁcult to compare their results. General-
ly, DBS-STN was found to increase the duration of total sleep
time and deep sleep, improve sleep efﬁciency, decreaseWASO,
whereas in most cases PLMS, RBD and RLS remained
unchanged. Table 3 presents the most important ﬁndings in
the previous 6 studies.
In our patients we found an improvement in subjective
measures of sleep, as assessed by PDSS and NMSS subdivision
for sleep, as well as reduced sleepiness on the ESS. However,
Table 1 – The details of the subjects' characteristics compiled with PSG data.
Pt Age Sex LED TS (min)
(pre/post)
SE (%)
(pre/post)
WASO
(min) (pre/post)
N1
(min) (pre/post)
N2
(min) (pre/post)
N3 (min)
(pre/post)
R (min)
(pre/post)
1 45 M 1620/1195 440/341 91.7/70.9 29.5/129.5 17.5/105 271.5/181.5 25/4.5 126/50
2 64 F 720/620 302.5/277.5 62.9/57.9 169/190.5 4/23 189/122 39.5/40 66/90.5
3 68 M 2275/1515 302.5/150 63/31.3 170.5/329.5 14.5/19 206.5/51.5 33/78 48.5/1.5
4 63 F 1200/990 329.5/182 68.6/38 133.5/279 10.5/38 195/59 92/74.5 32/8.5
5 58 M 2650/2750 360.5/217 75.1/45.1 114.5/248.5 10.5/93.5 248/93 22/2.5 80/28
6 64 F 1015/840 387.5/402.5 80.6/83.9 82.5/75 39.5/48 255.5/202 17/3.5 75.5/149
7 66 M 1540/1390 244.5/230 50.7/47.9 217/218.5 17/55 200/167.5 0/0.5 27.5/7
8 51 F 670/380 365/271.5 76/56.5 103.5/198.5 46.5/112.5 235.5/101.5 32.5/16.5 44/41
9 50 F 1670/640 326/177 67.8/51.2 145.5/161 20.5/32 250.5/104.5 15.5/25.5 39/15
10 59 F 750/590 366.5/201 76.4/41.9 76.5/232.5 25/41 262/101.5 64.5/46 15/11.5
F – female; M –male; LED – levodopa equivalent dose before surgery and 6 months after DBS programming; pre/post – results from preoperative
polysomnography and postpoperative polysomnography; PT – patient; TS – total sleep time; SE – sleep efﬁciency; WASO – wakefulness after
sleep onset.
Table 2 – The detailed results from the preoperative and follow-up polysomnographic recordings, non-motor and motor
symptoms scales. The initial evaluation was performed at a median of 1.1 week before surgery and the follow-up
evaluation at a median of 6.2 months post DBS programming.
Parameters Preoperative evaluation, median (range) Follow-up evaluation, median (range) Statistics
Total sleep time (min) 345.0 (244.5–440.0) 223.5 (150.0–402.5) p = 0.001a
Sleep efﬁciency (%) 71.8 (50.7–91.7) 49.5 (31.3–83.9) p = 0.02
WASO (min) 124.0 (29.5–217.0) 208.5 (75.0–329.5) p = 0.004a
Sleep latency (min) 10.5 (5.0–37.0) 13.2 (0.5–46.5) NS
REM sleep latency (min) 105.2 (21.5–289.5) 110.0 (4.5–346.0) NS
N1 (min) 17.2 (4.0–46.5) 44.5 (19.0–112.5) p = 0.01a
N2 (min) 241.8 (189.0–271.5) 103.0 (51.5–202.0) p = 0.00001a
N3 (min) 28.8 (0.0–92.0) 21.0 (0.5–78.0) NS
R (min) 46.2 (15.0–126.0) 21.5 (1.5–149.0) NS
Arousal index 17.9 (11.2–47.6) 20.1 (8.9–38.4) NS
PLMI 0.5 (0.0–67.8) 0.0 (0.0–65.6) NS
Apnea–hypopnea index 6.0 (0.0–36.6) 0.0 (0.0–1.1) NS
RBD 0 0 NS
NMSS 55.5 (23.0–106.0) 34.5 (14.0–73.0) p = 0.017b
PDSS 84.85(57.20–127.40) 95.95 (62.70–142.70) NS
ESS 9.5(1.0–23.0) 7.0 (1.0–19.0) NS
IRLSSc 25 (19–29) 18 (9–26) NS
PDQ39 60.5 (29.0–99.0) 46.5 (13.0–57.0) p = 0.034a
BDI 7.5 (3.0–16.0) 4.5 (0.0–15.0) NS
UPDRS II 18.00 (11.00–26.00) 12.00 (0.00–19.00) p = 0.037b
UPDRS IIId 17.5 (5.0–34.0) 16.00 (7.00–26.00) NS
UPDRS IV 8.00 (9.00–13.00) 5.0 (2.00–9.00) p = 0.0096b
a Paired t-test.
b Mann–Whitney–Wilcoxon test.
c IRLSS was done in patients who fulfilled criteria of International RLS Study Group for the diagnosis of RLS.
d ‘‘On-state’’ scores; BDI – Beck Depression Inventory, ESS – Epworth Sleepiness Scale ESS, IRLSS – International RLS Study Group Rating Scale,
NMSS – Non-Motor Symptoms Scale, NS – not statistically significant, PDSS – Parkinson's Disease Sleep Scale, PDQ39 – Parkinson's Disease
Quality of Life Questionnaire, PLMI – periodic limb movements index, RBD1Q – Single-Question Screen for RBD, UPDRS – Unified Parkinson's
disease rating scale, UPSIT – University of Pennsylvania Smell Identification Test, RBD – REM sleep behavior disorder, WASO –wakefulness after
sleep onset.
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on the follow-up PSG evaluation. We found a decrease in the
total sleep time and duration of the stage N2 with prolongation
of the lightest sleep stage N1. We also detected an increase in
duration of WASO. Compared to the previous studies, we
observed an improvement of periodic limb movements index,
however, this change was not statistically signiﬁcant.
We did not detect any impact of DBS-STN on subjective
severity of restless legs syndrome in our group of patients,
whereas the data from previous studies are inconsistent,some reporting improvement and others even deterioration
of RLS [ [11_TD$DIFF] 0]. At the initial evaluation 6 patients complained of
typical RBD symptoms and after DBS-STN the symptoms
subsided in one of these patients, but at the same time
appeared in 3 other patients. At the end of the study 8 patients
reported such symptoms, however, RBD was not observed in
any patient during PSG evaluations. In the majority of the
previous studies RBD remainedunchanged, however, Nishida
et al. demonstrated restoration of the normal pattern of REM
sleep [ [10_TD$DIFF] 1].
Table 3 – The summary of the previous studies including most important findings.
Study Number of
patients
Mean age
(years)
Mean disease
duration (years)
Increased parameters Unchanged
parameters
Decreased
parameters
Arnulf et al. 10a Range of
age: 40–60
NA Sleep efﬁciency; total sleep
time; N2 sleep; nocturnal
motor symptoms
Number of awakenings;
PLMS; RLS; RBD
WASO; axial
dystonia during the
night and early
morning dystonia
Iranzo et al. 11 63.6  7.8 17.3  9.1 Number of body position
changes; the longest
period of continuous sleep
PLMS, RBD arousal index
Cicolin et al. 5 63.8  3.3 13.8  4.9 Sleep efﬁciency; total sleep
time; the percentage of
stage 3–4 NREM sleep; the
longest period of
uninterrupted sleep
RBD, PLMS WASO, REM latency
Monaca et al. 10 57.4  5.2 12.1  2.6 Total sleep time, sleep
efﬁciency, deep slow-wave
sleep and paradoxical
sleep
Number of awakenings
during sleep
Nishida at al. 10 57.5  9.8 12.3  2.7 General sleep architecture;
slow-wave sleep and
normal REM sleep time;
WASO; REM sleep
without atonia
Baumann-
Vogel et al.
50 61  10 12  5 Total sleep time, sleep
efﬁciency, N3 sleep;
Sleep latency; the
duration of N1, N2, and
REM sleep; awakening
index; body position
changes; awakening
index; apnea–hypopnea
index; RLS, REM sleep
without atonia
WASO; REM sleep
latency, PLMS
a Only patients with severe akinetic idiopathic PD and chronic insomnia before surgery; NA – not available, PD – Parkinson's disease, PLMS –
periodic limb movement disorder, RBD – REM sleep behavior disorder, RLS – restless legs syndrome, RWA – REM without atonia, WASO –
wakefulness after sleep onset.
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severity of subjective sleep disturbances, other non-motor
symptoms and quality of life. We found a positive correlation
between subjective sleep disturbances and the general
perception of severity of non-motor symptoms. We also
detected a negative correlation between severity of motor
symptoms and the objective quality of sleep.
There have been several hypotheses regarding the mecha-
nism of DBS-STN impact on sleep in PD. Sleep could be
improved indirectly by alleviation of nocturnal motor symp-
toms, reduction in doses of antiparkinsonian medications, and
directly by inﬂuencing the sleep/wakefulness regulatory centers
[[12_TD$DIFF] 2]. The discrepancy between our results and the results from
the six previous studies are more than expected and difﬁcult to
explain.Most of these studiesuseddifferentmethodologies and
study designs, thus making it challenging to compare the
results. The age and disease duration of our patients were
generally similar to that in previous studies. Antiparkinsonian
medications, especially levodopa, amantadine and selegiline
may increase sleep fragmentation and induce insomnia. The
data on medications that patients were taking during the
previous studies are limited and the most detailed report is
given in the study by Baumann-Vogel et al. [[11_TD$DIFF] 0]. Compared to
this study our patients were taking signiﬁcantly higher doses of
medications. In our study on initial evaluation the levodopa
equivalent dose (LED) was 1411 673 mg and total levodopa
dose was 1155 694 mg, on follow up 1091 690 mg and 825
 790mg, whereas Baumann-Vogel et al. reported 1025 480,793 450, 369 376 and 309 342, respectively. The same ﬁve
patients (50%) were administered amantadine throughout the
study compared to only 18% of patients before DBS and none
after DBS in the study by Baumann-Vogel et al. Two patients
were on selegiline in our study, however, there is no
information about the intake of thismedication in the previous
studies.Wedidnotﬁndany correlationbetween themedication
type and subjective and objective sleep parameters, possibly
due to the small size of our group.
The discrepancy between subjective sleep measures along
with PDQ39 improvement and objective deterioration of PSG
parameters in our group remains unclear. It could be partially
explained by the observed improvement in mood, as assessed
by BDI, however, that difference was not statistically signiﬁ-
cant. Other factors that could have contributed to better
perceived sleep quality were increase in nocturnal mobility
(UPDRS part II question number 12, p = 0.034) and alleviation of
complications of dopaminergic therapy (UPDRS part IV,
p = 0.0096). Autonomic dysfunction symptoms, like nocturia,
may also worsen sleep, however, we did not detect any
relevant change in that domain. Finally, the placebo effect
cannot be excluded.
5. Future directionsIn summary, we found that DBS-STN improved quality of life,
subjective quality of sleep and sleepiness, however, contrary
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 5 1 4 – 5 1 8518to the previous studies the objective parameters of sleep
worsened after the surgery. These are the preliminary results
of the ﬁrst 10 patients included in our study and these ﬁndings
will be veriﬁed on a bigger group of patients.
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